The Impact of Facility Surgical Caseload Volumes on Survival Outcomes in Patients Undergoing Radical Cystectomy.
NCDB
bladder cancer
facility caseload
national cancer database
oncologic outcomes
overall survival
pelvic exenteration
radical cystectomy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Dec 2022
03 Dec 2022
Historique:
received:
08
10
2022
revised:
14
11
2022
accepted:
25
11
2022
entrez:
11
12
2022
pubmed:
12
12
2022
medline:
12
12
2022
Statut:
epublish
Résumé
The role of surgical experience and its impact on the survival requires further investigation. A cohort of patients undergoing radical cystectomy or anterior pelvic exenteration for localized bladder cancer between 2006 and 2013 at 1143 facilities across the United States was identified using the National Cancer Database and analyzed. Using overall survival (OS) as the primary outcome, the relationship between facility annual caseload (FAC) and facility annual surgical caseload (FASC) for those undergoing curative surgery was examined. Four volume groups (VG) depending on caseload using both FAC and FASC were defined. These included VG1: below 50th percentile, VG2: 50th−74th percentile, VG3: 75th−89th percentile, and VG4: 90th and above. Between 2006 and 2013, 27,272 patients underwent surgery for localized bladder cancer. The median OS was 59.66 months (95% CI: 57.79−61.77). OS improved significantly as caseload increased. The unadjusted median OS difference between VG1 and VG4 was 15.35 months (64.3 vs. 48.95 months, HR 1.19 95% CI: 1.13−1.25, p < 0.001) for FAC. This figure was 19.84 months (66.89 vs. 47.05 months, HR 1.25 95% CI: 1.18−1.32, p < 0.0001) for FASC. This analysis revealed a significant and clinically important survival advantage for curative bladder cancer surgery at highly experienced centers.
Identifiants
pubmed: 36497466
pii: cancers14235984
doi: 10.3390/cancers14235984
pmc: PMC9735798
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR001854
Pays : United States
Références
Eur Urol. 2011 Mar;59(3):317-22
pubmed: 21095055
BJU Int. 2012 Jul;110(2):226-32
pubmed: 22044615
Eur Urol. 2015 Jun;67(6):1056-1062
pubmed: 25530608
Eur Urol. 2011 May;59(5):775-83
pubmed: 21310525
J Urol. 2005 Aug;174(2):432-8
pubmed: 16006859
J Urol. 2012 Dec;188(6):2139-44
pubmed: 23083864
J Urol. 2008 Sep;180(3):820-8; discussion 828-9
pubmed: 18635233
BJU Int. 2018 Feb;121(2):217-224
pubmed: 28594471
BJU Int. 2014 Jul;114(1):46-55
pubmed: 24219110
Cancer. 2013 Oct 1;119(19):3546-54
pubmed: 23839861
Urol Int. 2020;104(7-8):559-566
pubmed: 32272471
Urol Oncol. 2009 Jul-Aug;27(4):417-21
pubmed: 19573772
J Urol. 2004 Dec;172(6 Pt 1):2145-52
pubmed: 15538220
Urol Oncol. 2010 May-Jun;28(3):243-50
pubmed: 19395287
J Natl Cancer Inst. 2007 Aug 1;99(15):1171-7
pubmed: 17652279
Urol Oncol. 2018 Jun;36(6):308.e11-308.e17
pubmed: 29628316